Latest Stories

Don’t miss our hot and upcoming stories
Can Eli Lilly and NVIDIA’s AI Supercomputer Redefine Drug Discovery Timelines and Ignite a $40 Billion AI-Biopharma Revolution?

Key Insights:• Lilly builds one of pharma’s first NVIDIA-powered DGX SuperPODs, training AI on millions…

ByByAnuja Singh Nov 1, 2025
Could the Algen Biotechnologies – AstraZeneca $555 Million AI-Driven Drug-Discovery Pact Redefine How Immunology Therapies Are Developed?

Key Highlights / Executive Take-aways: Strategic Significance of the PartnershipThe alliance between Algen Biotechnologies and…

ByByAnuja Singh Oct 26, 2025
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?

Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to…

ByByAnuja Singh Oct 26, 2025
Could Cohere’s New Paris Office Accelerate AI Adoption Across Europe’s Healthcare and Biopharma Sector?

Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large…

ByByAnuja Singh Sep 16, 2025
Scroll to Top